Solvonis Therapeutics says a new analysis of its ketamine-based alcohol-use-disorder candidate SVN-001 shows a 67 per cent reduction in heavy-drinking days versus placebo at weeks 17 to 20.

The company presented the finding as a breakthrough, also claiming the data compare favourably with rival treatments. But cross-trial comparisons are not proof of superiority: different studies enrol different patients and use different designs.

The analysis is company-funded and has not been peer-reviewed. Independent experts say the results need confirmation in larger, controlled trials before any conclusions about efficacy can be drawn.

Alcohol-use disorder affects millions and has few effective drug options, which is why the field is watching new approaches closely. Solvonis is also outlining expansion plans in Europe and the US.

Investors cheered the announcement, but clinicians urge patience. The real test will be whether the effect holds up in the company’s next phase of trials. The company said it will share more detailed data at upcoming medical meetings.